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IL-6 plays a central role in supporting pathological TH2 and TH17 cell development and inhibiting the
protective T regulatory cells in allergic asthma. TH17 cells have been demonstrated to regulate allergic
asthma in general and T-bet-deficiency-induced asthma in particular. Here we found an inverse correlation
between T-bet and Il-6 mRNA expression in asthmatic children. Moreover, experimental subcutaneous
immunotherapy (SIT) in T-bet(2/2) mice inhibited IL-6, IL-21R and lung TH17 cells in a setting of asthma.
Finally, local delivery of an anti-IL-6R antibody in T-bet(2/2) mice resulted in the resolution of this allergic
trait. Noteworthy, BATF, crucial for the immunoglobulin-class-switch and TH2,TH17 development, was
found down-regulated in the lungs of T-bet(2/2) mice after SIT and after treatment with anti-IL-6R antibody,
indicating a critical role of IL-6 in controlling BATF/IRF4 integrated functions in TH2, TH17 cells and B cells
also in a T-bet independent fashion in allergic asthma.
A
llergic asthma is aworld-wide increasing disease characterized by chronic airway inflammation associated
with recurrent episodes of wheezing, breathlessness and coughing in response to otherwise innocuous
environmental stimuli1. Subcutaneous Immunotherapy (SIT) has been used successfully in the last two
decades as therapy for this disease2–5. Interleukin-6 (IL-6) is a pro-inflammatory cytokine influencing T and B cell
functions relevant also to asthma exacerbation in children6. IL-6 is produced by dendritic cells upon allergen
challenge that induces both, TH2 and TH17 differentiation in allergic asthma7. In fact, IL-6 in conjunction with IL-
21 induces TH17 cells8. It has been demonstrated that TH17 cells are involved in the pathogenesis of allergic asthma,
especially in the absence of T-bet9–13. Targeted deletion of T-bet, a T-box transcription factor that trans-activates
the Interferon-gamma (IFN-c) gene in TH1 cells, is associated with an aggravated asthmatic trait14.We previously
demonstrated that patients with asthma have increased soluble IL-6R in their airways. Local treatment with a-IL-
6R antibodies led to a 50% reduction of STAT-3 but not STAT-1 phosphorylation in the lung of treated mice as
compared to control treated mice. Moreover, we showed that blockade of IL-6R signaling leads to cell death of
lung effector T cells by activating regulatory T cells in experimental asthma15,16. Here we found that in asthmatic
children, an increase of IL-6 mRNA values coexists with low values of T-bet mRNA expression in their PBMCs.
Furthermore, experimental SIT decreased IL-6, IL-21R, as well as Interferon regulatory factor 4 (IRF4) encoded
by the Irf4 gene and lung TH17 cells in T-bet(2/2) mice in a setting of asthma. Finally, local treatment of T-bet(2/2)
mice with an antibody against the IL-6R resulted in the resolution of the allergic trait. Notably, Basic leucine
zipper transcription factor ATF-like, also known as BATF, a transcription factor essential for the development of
TH2 and TH17 cells and immunoglobulin-class-switch of B cells17–20 was found down-regulated in the lungs of T-
bet(2/2) mice after SIT and after in vitro stimulation with a-IL-6R antibody. These results indicate an important
role of IL-6 in controlling integrated functions of BATF in TH2, TH17 and B cells also in a T-bet independent
manner in allergic asthma21–23.
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Results
Here, we found an inverse correlation between Il-6 and T-betmRNA
expression in the peripheral blood mononuclear cells (PBMC) of
small children with asthma (Figure 1a and Supplementary Table
1). T-bet has been previously reported to be down-regulated in CD41
T cells in asthmatic children24 and IL-6 was found to be up-regulated
in asthmatic patients25–27.
In this study, in amurinemodel of asthma (Figure 1b), we found a
spontaneous significant up-regulation of IL-6 in lung tissue as well as
in lung CD41 T cells from asthmatic T-bet(2/2) mice as compared
to those isolated from wild type littermates (Figure 1c and d,
respectively).
IL-6 up-regulates BATF, a transcription factor involved in both
TH17 development and immunoglobulin class switch18,20. We thus
next looked at the serum level of IgE of wild type and T-bet(2/2) mice
in a murine model of allergic asthma. We found a statistically sig-
nificant up-regulation of IgE in the serum of asthmatic T-bet(2/2)
mice (Figure 2a). We next investigated whether BATF was induced
in lung CD41 T cells isolated from T-bet(2/2) mice. As shown in
Figure 2b, BATF was spontaneously up-regulated in lung CD41 T
cells isolated from T-bet(2/2) mice and both wild-type and T-bet(2/2)
asthmatic mice had a significant up-regulation of BATF in lung
CD41 T cells (Figure 2b).
We then looked for the TH17 cell signature transcription factor,
RAR-related orphan receptor (ROR)ct8,28. RORct was found to be
up-regulated but only in the lungs of naı¨ve T-bet(2/2) mice and in the
lungs of asthmatic wild type mice (Figure 2c).
Because BATF was found to be induced in conjunction with IL-6
in T-bet(2/2) mice, we isolated lung CD41 T cells from naı¨ve
wild-type and T-bet(2/2) mice and stimulated them with IL-6. We
found that BATF was induced by IL-6 in T-bet(2/2) CD41 T cells but
not in wild-type CD41 T cells (Figure 2d). However, we observed a
significant increase of RORct in the T-bet(2/2) CD41 T cells com-
pared to the wild-type, but no further up-regulation in either wild-
type or T-bet(2/2) CD41 T cells after IL-6 stimulation (Figure 2e),
indicating that RORct is controlled by other factors and by T-bet29,30.
TH17 cells can be induced by IL-6 in conjunction with IL-2129,30 and
BATF is known to play an important role in this context21,23.We then
analyzed IL-21 and found that this cytokine was up-regulated in
asthma in wild-type and T-bet(2/2) mice (Figure 3a). Similarly, the
IL-21R was found up-regulated in the lungs of T-bet(2/2) mice both
spontaneously and in a setting of asthma (Figure 3b). Interferon
regulatory factor 4 is another transcription factor involved in TH17
cell differentiation31,32. Moreover, IL-21 has been shown to induce
IRF4 and BATF integrated functions in TH17 cells leading to IL-10
production in these cells23,32. IRF4 has been recently found elevated in
asthmatic patients33. Consistently, we found an up-regulation of Irf4
mRNA expression in the lung of both wild-type and T-bet(2/2) OVA
sensitized and challenged mice (Figure 3c). Consistent with our
findings at the transcriptional level, we found significantly higher
IL-17A protein levels in the supernatants of cultured CD41 T cells
isolated from T-bet(2/2) mice after asthma induction as compared to
the levels measured in the CD41 T cell supernatants from wild-type
littermates (Figure 3d). TH17 cells were shown to produce IL-10
which is regulated by BATF-JUN-IRF4 and c-maf21–23,34,35, a possible
mechanism bywhich TH17 cells auto-regulate themselves34.Whenwe
analyzed IL-10 in this context, we found increased levels of
this cytokine in CD41 T cells from T-bet(2/2) mice compared to
Figure 1 | Increased IL-6 in asthma in the absence of T-bet. (a) Correlation betweenmRNAvalues of healthy pre-school control children (left panel) and
asthmatic (right panel) children. (b) Experimental design of a murine model of allergic asthma in wild-type and T-bet(2/2) mice. Mice received 100 mg
OVA/Alum intraperitoneally (i.p.) and 2 mg/ml OVA intranasally (i.n.). (c) Increased expression of Il-6 mRNA in murine lung tissue by qPCR in T-
bet(2/2) naı¨ve (PBS) and asthmatic mice (OVA). (d) Increased IL-6 in murine lung CD41 T cells in T-bet(2/2) asthmatic mice after intracellular flow
cytometric analysis.
www.nature.com/scientificreports
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wild-type mice (Figure 3e and f). In conclusion, we found an up-
regulation of TH17 cells expressing both pro-inflammatory and anti-
inflammatory cytokines in the lung of asthmatic T-bet(2/2) mice in a
setting of allergic asthma. These cells probably developed via IL-6
and IL-21. T-bet(2/2) mice have increased CD41CD251 effector T
cells in their lungs after allergen sensitization but in the absence of
allergen challenge36. Moreover, IL-2 inhibits T regulatory cell
development when given intranasally in experimental asthma37.
Here, we found that IL-2 was up-regulated in the lungs of T-bet
deficient asthmatic mice under tolerogenic conditions (without cost-
imulation) as compared to their wild-type littermates (Figure 4a and
Supplementary Figure 1). Since TH17 cells and Treg cells are con-
trolled reciprocally and high levels of IL-6 induce TH17 cells while
inhibiting Treg cells, we next analyzed CD41CD251Foxp31 T cells in
the lungs of wild-type and T-bet(2/2) mice. We observed a reduced
number of Foxp31 Treg cells in both wild-type and especially in T-
bet(2/2) mice after sensitization and challenge with OVA (Figure 4b).
This decrease represents a significant proportion of the T regulatory
cells that in the lung represent only 5% of the total CD41 T cells.
Moreover, T-bet(2/2) mice showed significantly lower numbers of
Treg cells in the asthma model compared to wild-type mice
(Figure 4b). These data indicate that TH17 skewing and T regulatory
inhibiting conditions are sustained environmental conditions in the
lungs of T-bet(2/2) mice in an experimental asthma model.
A long-term cure for asthma might be the SIT2. To investigate a
potential role of IL-6 in SIT and in T-bet(2/2) mice, we applied the
protocol of subcutaneous immunotherapy (SIT) in a second murine
model of asthma in T-bet(2/2) mice as shown in Figure 5a. We
found that Il-6 mRNA was also significantly induced in this model
of allergic asthma in the lung of T-bet(2/2) mice as compared to non
asthmatic mice (Figure 5b). Moreover, immunotherapy led to a
down-regulation of Il-6 mRNA in the lungs of treated mice
(Figure 5b). To analyze the role of TH17 cells in SIT, we next analyzed
the expression ofRorctmRNA in the lung, which we found increased
in asthma and decreased after SIT (Figure 5c). IL-6 induces BATF
downstream of the IL-6R pathway38. Consistent with a reduction of
IL-6, we found that BATF was decreased (Figure 5d) after SIT. IRF4,
which acts together with BATF at the IL-10 promoter23, was also
found down-regulated after immunotherapy (Figure 5e) along with
IL-21 and IL-21R (Figure 5f and g). Because the factors inducing
TH17 cells were down-regulated in immunotherapy in T-bet(2/2)
mice, we looked for IL-17A and IL-10. Both cytokines were found
decreased after immunotherapy (Figure 5h und i). Finally, IL-2, a
marker of TH cell differentiation was also found down-regulated
(Figure 5j). Considering that we could not find an up-regulation of
T regulatory cells in this model, these results indicate a possible role
for IL-6 in controlling TH17 cells producing IL-17A and IL-10 in
asthma that could be inhibited by SIT in the absence of T-bet.
We have previously demonstrated that local blockade of IL-6R in
the lung of wild-type mice led to amelioration of the allergic asth-
matic reaction15. In this study we found that T-bet(2/2) mice treated
with a-IL-6R antibody, as indicated in Figure 6a, had reduced airway
inflammation (Figure 6b) and decreased IgE levels in the serum
(Figure 6c). IL-6 is known to play an important role in the differ-
entiation of activated B cells into antibody-producing cells39. We
found here that B cells (CD191) were decreased after a-IL-6R anti-
body treatment (Figure 6d), that they express the IL-6R and are
induced in the asthma model (Supplementary Figure 2). We also
Figure 2 | IL-6 induces BATF in the absence of T-bet in lung CD41 T cells from naı¨ve and asthmatic mice. (a) Increased levels of IgE in murine
blood serum in T-bet(2/2) mice (n5 9–17mice per group). (b) Increased BatfmRNA expressionmeasured by qPCR in isolatedmurine lung CD41 T cells
from T-bet(2/2) mice (n 5 3–5 mice per group). (c) Increased expression of RorctmRNA in murine lung tissue of T-bet(2/2) mice. (d, e) Batf and Rorct
mRNA expression after quantitative real time PCR in naı¨ve lung murine CD41 T cells cultured with a-CD3 and a-CD28 alone (Med) or with IL-6
(20 ng/ml) (Med1IL-6) (n 5 3–5 mice per group). BATF and not RORct were induced by IL-6 in lung CD41 T cells isolated from T-bet(2/2) mice.
Students t test was used to calculate statistical significances. * P # 0.05, ** P # 0.01, *** P # 0.001. Results are expressed as mean 6 s.e.m.
www.nature.com/scientificreports
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observed a down-regulation of CD41 T cells (Figure 6e) as well as of
the TH2 cytokines IL-4, IL-5 and IL-13 after a-IL-6R antibody treat-
ment in T-bet(2/2) mice (Figure 6f, g, h, respectively).
BATF deficient mice have been demonstrated to lack TFH cells
which are important to prime B cell mediated immune responses17.
Moreover, BATF has been recently shown to play a central role in
inducing TH2 cells reminiscent of the role of IL-617–19. We thus
hypothesized that IL-6 controls BATF in allergic asthma. To prove
this, we analyzed BATF gene expression in total lung cell cultures
isolated from OVA-sensitized T-bet(2/2) mice that were treated with
the anti-IL-6R antibody in vitro (Figure 7a) . We found that BATF
which was induced in T-bet deficient mice (Figure 7b) was signifi-
cantly reduced after in vitro stimulation with anti-IL-6R antibody
treatment in lung cells of T-bet(2/2) mice. Rorct mRNA expression
was not changed after anti-IL-6R treatment neither in wild-type, nor
in T-bet(2/2) mice (Figure 7c). C-maf (Figure 7d) was found down-
regulated only in wild-type mice after administration of the anti-IL-
6R antibody. IL-6 induces IL-21 via the transcription factors BATF38
and c-maf40,41. Consistently, we found significantly reduced IL-21 in
the lung cells that were in vitro treated with anti-IL-6R antibody. We
then asked whether the down-regulation of BATF and IL-21 would
result in decreased IL-17A expression. IRF4 has been shown to inter-
act with BATF at the IL-17A promoter. However, we could not
observe a downregulation of IRF4 after anti-IL6R antibody treatment
in vivo (Figure 8a and b). Similarly, IL-17A was not specifically
down-regulated by anti-IL-6R antibody treatment in vivo in T-bet
deficient mice (Figure 8c).
It has been recently reported that BATF cooperates with IRF4 and
STAT3 in cells stimulated with IL-21 to produce IL-1021–23.We then
looked at IL-21R and IL-10 after anti-IL-6R antibody treatment. We
Figure 4 | IL-2 expression is increased in the lung of T-bet(2/2) asthmatic mice. (a) Increased IL-2 protein expression in the supernatants of lung cells
isolated from T-bet(2/2) asthmatic mice and cultured with a-CD3 and OVA (500 mg/ml) for 24 hours as indicated. (b) Decreased CD41CD251Foxp31
Treg cells in T-bet(2/2) mice sensitized and challenged with OVA as described in Figure 1 and after flow cytometric analysis. Students t test was used to
calculate statistical significances. * P # 0.05, ** P # 0.01, *** P # 0.001. Results are expressed as mean 6 s.e.m.
Figure 3 | Increased IL-21, IL-17A and IL-10 expression in lung CD41T cells of T-bet(2/2) asthmaticmice. (a) Increased Il-21mRNA expression in lung
CD41 T cells isolated from asthmatic T-bet(2/2) mice. (b) Increased Il-21R mRNA expression in murine lung tissue from asthmatic T-bet(2/2) mice.
(c) Increased Expression of Irf4 mRNA in asthmatic murine lung tissue. (d) IL-17A level measured in the supernatants of murine lung CD41 T cells
isolated from T-bet(2/2) asthmatic mice and cultured for 24 h with a-CD3 and a-CD28 (n 5 4–6 mice per group). (e) Increased number of lung
CD41IL-101 T cells in T-bet(2/2) asthmatic mice after intracellular flow cytometric analysis. (f) Increased IL-10 release by lung CD41 T cells from
T-bet(2/2) micemeasured by ELISA in the supernatants of these cells after 24 hours of cell culture with a-CD3, a-CD28 antibody challenge. Students t test
was used to calculate statistical significances. * P # 0.05, ** P # 0.01, *** P # 0.001. Results are expressed as mean 6 s.e.m.
www.nature.com/scientificreports
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found that T-bet(2/2) asthmatic mice had decreased Il-21R mRNA
and IL-10 mRNA in their lungs after anti-IL-6R antibody treatment
(Figure 8d and e). It is thus possible that IL-6 controls the expression
of BATF, IL-21 and IL-21R on TH2 and TH17 cells in the lung in a
setting of allergic asthma in T-bet(2/2) mice.
Discussion
IL-6 is a pleiotropic cytokine that plays an important role in inflam-
mation and cancer42. It is released by cells of the innate and adaptive
immune-response. As it induces the proliferation of T cells as well as
B cells its blockade has an impact on immune responses which lead to
IgE hyper-production and to the expansion of effector TH17 and TH2
cells seen in the lungs of asthmatic patients. These findings show the
relevant contribution of IL-6 to the pathogenesis of asthma.
The transcription factor T-bet, which is known to transactivate the
Ifnc gene, was found to be down-regulated in asthmatic patients. In
this paper, we observed that the PBMC of children with asthma have
lower values of T-betmRNA that coexist with relative higher levels of
IL-6 mRNA. Further epigenetic studies are underway in these chil-
dren to see if T-bet inhibits IL-6 at the promoter level or if pSTAT-3
downstream of IL-6 inhibits T-bet expression or bothmechanism are
present in asthma. In this paper we analyzed the effect of T-bet on IL-
6 expression and the effect of IL-6 signal transduction in the presence
and absence of T-bet in different settings of asthma. Here, we found
that T-bet(2/2) mice, which have a more severe phenotype of asthma
than wild-type mice, show an increased production of IL-6 in lung
tissue as well as CD41 T cells. In addition, downstream of IL-6, T-bet
deficient lung CD41 T cells show increased expression of Batf, the
transcription factor not only orchestrating TFH cells and B cells in the
B cell zone in the lymphatic organs, but also controlling TH17 cell
development17–19. Moreover, we found that IL-6 does not control
RORct mRNA expression in lung CD41 T cells. Our data suggest
that T-bet inhibits the development of Th17 cells by inducing IL-21R
and inhibiting IL-10 expression in lung CD41 T cells in asthma.
We also found that OVA sensitization and challenge in T-bet
deficient mice led to an up-regulation of IL-21, which can then bind
to its receptor and further induce the interaction of BATF/IRF4 at the
IL-10 and IL-17A promoters. This results in the hyperproliferation of
TH2 and TH17 cells seen in asthmatic T-bet deficient mice. Because
TH17 and Treg cells control each other, we went on to investigate
CD41CD251Foxp31 Treg cells. Although Treg numbers were
decreased in both wild-type and T-bet(–/–) mice after allergen expo-
sure, T-bet(–/–) asthmaticmice showed significantly lower numbers of
Treg cells, which is probably secondary to the overproduction of IL-6
in thesemice. However, the exact mechanism on how IL-6 controls T
regulatory cells needs further investigation.
SIT is a successful therapy for allergic asthma and is accompanied
by reduced IgE levels, inflammation and AHR2. However, the
immunological changes present in this treatment are not clearly
documented. To attempt to improve this understanding, we asked
whether IL-6 regulation would be involved in this treatment. We
found that SIT decreased not only IL-6, but also RORct, BATF,
Figure 5 | DecreasedmRNA expression of different transcription factors and cytokines involved in TH17 differentiation after immunotherapy (SIT) in
T-bet(2/2) mice. (a) Experimental design of the murine asthma model with immunotherapy. Mice received 100 mg OVA/Alum intraperitoneally (i.p.),
1000 mgOVA subcutaneous (s.c.) and 2 mg/mlOVA intranasally (i.n.). (b–j)mRNA expression of Il-6 (b),Rorct (c),Batf (d), Irf4 (e), Il-21 (f), Il-21R (g),
Il-17A (h), Il-10 (i) and Il-2 (j) in lung tissue of T-bet(2/2) mice before and after SIT (n5 3–6mice per group). Results in this figure are expressed as mean
6 s.e.m. Students t test was used to calculate statistical significances in this figure. * P # 0.05, ** P # 0.01, *** P # 0.001.
www.nature.com/scientificreports
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IRF4 and IL-21R in the lungs of treated asthmatic T-bet(–/–) mice.
These findings were accompanied by reduced effector TH17 cells, as
well as IL-10 and IL-2 production.
We then asked whether blockade of the IL-6R would recapitulate
the results seen after subcutaneous immunotherapy in T-bet defi-
cient mice. We found that local anti-IL-6R antibody treatment had
an even higher effect on the immunological markers inhibited by the
SIT in the lung of T-bet deficient mice. Specifically, we observed a
specific down-regulation of BATF, IL-21/IL-21R and IL-10 after
anti-IL-6R antibody treatment. This resulted in a decreased differ-
entiation of naı¨ve T cells into TH2 cells. However, the down-regu-
lation of IL-17A after anti-IL-6R antibody treatment was not
statistically different from IgG treatment for yet unknown reasons.
One possibility could relate to our findings showing that IL-6 induces
BATF and not RORct in the CD41 T cells from T-bet deficient mice.
Similarly to IL-17A also IRF4 was not significantly down-regulated
by anti-IL-6R antibody treatment as compared to IgG. This is con-
sistent with an IL-17A inducing role of IRF4 on IL-17A. In fact, it has
been previously demonstrated that retrovirus over-expressing IRF4
induce IL-17A43. Moreover, IRF4 in conjunction with IL-6 induces
Rorct. Thus the residual IRF4 after anti-IL-6R antibody treatment
might be responsible for the presence of IL-17A and RORct. Thus it
is possible that IL-17Amodulation in asthma in the absence of T-bet
requires both IL-6 and probably other not yet described factors that
regulate RORct such as IRF4. Further studies in this direction are
underway in our laboratory. The anti-IL-6R treatment also led to a
down-regulation of IL-21/IL-21R. IL-21 is an important cytokine
that maintains the effector cells and has received attention because
of its role in auto-immunity44. In contrast to IL-21R which is dis-
tributed to B, T, NKT cells and DCs, IL-21 is limited and support the
effector T cells and NKT cells44. Finally we found a down-regulation
of TH2 cytokines and IgE serum levels after anti IL-6R antibody
treatment. It is possible that the IL-21/IL-21R reflects a decrease in
Th2 cells as IL-21 has been described to be a Th2 cytokine45. These
inhibitory effects on lymphocytes were also evident by the inhibition
of the hyper-proliferation of CD41 T cells and B cell maturation in
the lung of anti-IL-6R treated mice.
Taken together, these data demonstrated a multi target immune-
regulatory effect of anti-IL-6R antibody immunotherapy that works
by inhibiting the main cellular components of allergic asthma in the
absence of T-bet. This therapy results in reduction of TH2 and mar-
kers of TH17 cells, inflammation and IgE production. We found a
Figure 6 | Reduction of IgE, inflammation and TH2 cytokines in a-IL-6R antibody treated asthmatic T-bet(2/2) mice. (a) Experimental design of a
murine asthmamodel and the a-IL-6R antibody therapy. Mice received 100 mg OVA/Alum intraperitoneally (i.p.) and 2 mg/ml OVA intranasally (i.n.).
Some of the mice also received 75 mg of a-IL-6R antibody or IgG. (b) Decreased pathological Score of the inflammation and corresponding histological
sections of the lungs stained with H&E in anti-IL-6R antibody treated mice. (c) Decreased levels of IgE in blood serum of T-bet(2/2) mice treated with a-
IL-6R antibody in vivo. One of three similar experiments are shown with three to five mice per group. (d,e) Decreased number of CD191 B cells (d) and
CD41 T cells (e) isolated from the lungs of T-bet(2/2) sensitized and challenged mice (n5 4–21 mice per group) and in vivo treated with anti-IL6R
antibody. (f–h) ELISA of IL-4 (f), IL-5 (g) and IL-13 (h) in the supernatants of total lung cell cultures fromOVA-challenged and a-IL-6R antibody treated
mice. Cells were cultured for 24 hwith a-CD3 anda-CD28 (n5 7–8mice per group). Statistical significances in this figure were evaluated with a Students
t test.
www.nature.com/scientificreports
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Figure 7 | Reduced BATF, c-maf and IL-21 expression after in vitro treatment with a-IL-6R antibody. (a) In vitro treatment withOVA (500 mg/ml) and
additionally anti-IL-6 R antibody or IgG (15 mg/ml). (b,c) Reduced expression of Batf (b), but not Rorct (c) after treatment with a-IL-6R antibody.
(d) c-mafmRNA expression in total lung cells fromuntreated, OVA-treated and/or a-IL-6R antibody treatedwild-type andT-bet(2/2)mice (n5 3–5mice
per goup). (e) Decreased Il-21mRNA expression in lung CD41 T cells isolated fromwild-type and T-bet(2/2) mice after a-IL-6R antibody treatment. Cells
were cultured for 24 h with a-CD3 and a-CD28 (n 5 10–16 mice per group). Data are mean 6 s.e.m. Students t test was used to calculate statistical
significances. * P # 0.05, ** P # 0.01, *** P # 0.001.
Figure 8 | Decreased IL-21R and IL-10 in T-bet deficientmice treated in vivo with anti-IL-6R antibody. (a) Experimental design of anti-IL-6R antibody
treatment in vivo. 100 mg OVA/Alum was administered to the mice intraperitoneally (i.p.) and 2 mg/ml OVA intranasally (i.n.). Some of the mice also
received 75 mg of a-IL-6R antibody or IgG. (b) Irf4mRNA expression in lung tissue of T-bet(2/2)mice (n 5 8–9mice per group). (c) IL-17Ameasured by
ELISA in the supernatants of total lung cell cultures of T-bet(2/2) mice sensitized and challenged in vivo with OVA and treated in vivo with a-IL-6R
antibody. (d) Decreased expression of Il-21RmRNA in lung tissue from T-bet deficient mice treated with anti-IL-6R antibody (n 5 3–6mice per group).
(d) Decreased IL-10 in the supernatants of total lung cell cultures of T-bet(2/2) mice sensitized withOVA treated in vivowith a-IL-6R antibody . Students t
test was used to calculate statistical significances. * P # 0.05, ** P # 0.01, *** P # 0.001. Results are expressed as mean 6 s.e.m.
www.nature.com/scientificreports
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central regulatory role of BATF-IRF4 complex downstream of the IL-
6R in mediating this effect because controlling both TH2, TH17 and B
cells that is important for the development of new immune-thera-
peutical strategies for allergic asthma.
Methods
Human studies. Isolation of PBMCs. Heparinized blood was transferred to a 15 ml
sterile tube and diluted with an equal volume of PBS, inverted and carefully stratified
on Ficoll-Hypaque. After centrifugation, the layer of peripheral blood mononuclear
cells (PBMCs), between plasma and Ficoll, was carefully transferred into a new 15 ml
tube. On the one hand the RNA was isolated by using PeqGold RNA Pure according
to themanufacturer´s protocol (PeqLab, Erlangen, Germany). On the other hand RNA
was isolated with an AllPrep DNA/RNA Mini Kit (Quiagen, Hilden, Germany).
Quantitative real time PCR was performed as described below. This study was
approved by the ethics committee of the Friedrich-Alexander University Erlangen-
Nu¨rnberg, Germany (Re-No 4435). Informed consent was obtained from the parents
of the all human participants (children) of this study.
Mice. Wild-type and T-bet(2/2) mice (the latter generous gift from Prof Laurie
Glimcher) were on a Balb/c genetic background. The experiments were performed
with male mice at the age of 6–8 weeks. The animals were bread in the animal facility
adjacent to our institute with temperature control and had free access to food and
water. All experiments were performed with approved licences (23-177-07/G09-1-
008 from ethical review board Rheinland-Pfalz and 54-2532.1-2/10 from government
of Mittelfranken, Bavaria).
Murine model of allergic asthma and antibody treatment. Wild-type mice and T-
bet(2/2) mice received an intraperitoneal injection of 100 mg OVA (Calbiochem,
San Diego, CA) complexed with 10% alum (Sigma Aldrich, Steinheim, Germany) on
day 0. On days 7, 8 and 9 the animals were treated with OVA or PBS intranasally
(2 mgOVA/ml PBS in solution). Some of themice also received 75 mg/day a-mIL-6R
monoclonal antibody MR16-1 (Chugai Pharmaceuticals) or rat IgG control (R&D
Systems, Wiesbaden) intranasally about 30 minutes before the allergen challenge on
days 7 and 8. On day 10 the mice were sacrificed to isolate lung cells as described
below.
Murine model of immunotherapy. The immunotherapy model was modified from a
previously described protocol46. Briefly, on days 0 and 2 T-bet(2/2) mice were intra-
peritoneally immunized with 100 mg Ovalbumin (Calbiochem, San Diego, CA)
complexed with 10% alum (Sigma Aldrich, Steinheim, Germany) or PBS. The
immunotherapy group received 1000 mg OVA subcutaneously on days 19, 21 and 23.
On days 33, 34 and 35 the mice received OVA intranasally (2 mg OVA/ml PBS in
solution) and on day 36 the mice were sacrificed.
Collection and analysis of the BAL. BALF of the right lung was performed 24 h after
the last allergen challenge with 0.8 ml saline for two times. BALF was collected and
centrifuged at 1500 rpm for 5 min. The supernatants were frozen and subsequently
analyzed by ELISA. The cell pellets were resuspended in 1 ml PBS and an aliquot was
stained with trypan blue solution and cells were counted using a Neubauer chamber.
Eosinophils were detected by fluorescence-activated cell sorting (FACS) analysis. The
cell surface staining was performed with antibodies against CD3-Fitc (eBioscience,
Frankfurt, Germany), GR-1-Pe (BD Bioscience, Heidelberg, Germany), CD45R-
PeCy5.5 (eBioscience, Frankfurt, Germany) and CCR3-APC (BD Bioscience,
Heidelberg, Germany) for 30 min at 4uC.
Histological analysis. Lung tissues were analyzed by using paraffin-embedded tissue
slices for histology. After staining with Hematoxylin/Eosin peribronchial and peri-
vascular inflammation was assessed by a pathologist blinded to the experimental
group assignments of the individual lungs. Inflammation was graded by using a semi-
quantitative scoring system with a range pending between 1 (mild) and 4 (severe) as
described before37.
Isolation of lung CD41 T cells. CD41 T cells were purified as previously described47
from isolated lung cell suspension by incubation with anti-mouse CD4 L3T4
microbeads and positively sorted in a magnetic cell sorter system according to the
manufactorer´s protocol (MACS; Miltenyi Biotech, Germany). CD41 T cells were
cultured in RPMI with plate-bound a-CD3 and soluble a-CD28 for 24 h in a density
of 106 cells/ml. Afterwards ELISA or RNA isolation was performed.
Flow cytometric analysis and intracellular staining. Total lung cells were stained with
anti-CD4-Alexa488, anti-CD25-PerCp-Cy5.5 (BD Bioscience, Heidelberg,
Germany), anti-CD19-Fitc and anti-IL-6R-Pe (eBioscience, Frankfurt, Germany)
antibodies for 30 min at 4uC and washed once before measuring. For intracellular
staining with IL-10 or IL-6 cells were cultured in RPMI medium at a concentration of
2 3 106 cells/ml over night with plate-bound a-CD3 (2 mg/ml) and soluble a-CD28
(2 mg/ml). The next day cells were stimulated with PMA (1 ng/ml, Sigma-Aldrich,
Steinheim, Germany), Ionomycin (1 mM, Sigma-Aldrich, Steinheim, Germany) and
GolgiStop (BD Bioscience, Wiesbaden, Germany). After centrifugation the cells were
incubated with surfacemarkers for 30min at 4uC.Afterwards the cells were fixedwith
fixation/permeabilization solution (eBioscience, Frankfurt, Germany) for 35 min at
4uC and then washed with permeabilization buffer (eBioscience, Frankfurt,
Germany). Subsequently, the cells were incubated with antibodies against IL-10
conjugated with APC (BDBioscience,Wiesbaden, Germany) or IL-6 conjugated with
Pe (eBioscience, Frankfurt, Germany) for 30 min at 4uC in permeabilization buffer
and washed once. The samples were acquired by using a FACS-Calibur and analyzed
with FlowJo.
ELISA.Mouse IL-2, IL-4, IL-5, IL-10 and total IgE were detected by using OptEIATM
sandwich ELISA kits from BD Bioscience (Heidelberg, Germany). Mouse IL-13 and
IL-17 were detected by using a DuosetTM sandwich ELISA kit from R&D Systems
(Wiesbaden, Germany).
RNA isolation and quantitative real time-PCR. Total lung tissue was homogenized
and total RNA was then extracted by using PeqGold RNA Pure according to the
manifacturer’s protocol (PeqLab, Erlangen, Germany). Cells were directly resus-
pended in PeqGold RNA Pure for RNA isolation. RNA (1 mg) was then reverse
transcribed using the first strand cDNA synthesis kit for RT-PCR (MBI Fermentas,
Sat. Leon-Rot, Germany). The resulting template-cDNA was amplified by quant-
itative real-time PCR using SsoFast EvaGreen Supermix (Bio-Rad Laboratories,
Mu¨nchen, Germany). The qPCR was performed with a cycle of 2 min 98uC, 50 cycles
at 5 s 95uC, 10 s 60uC, followed by 5 s 65uC and 5 s 95uC in a CFX96 Touch Real-Time
PCR Detection System (Bio-Rad Laboratories). The primers and sequences used for
mouse were as follows: mRORcT (59-GTG TGC TGT CCT GGG CTA CC-39,
59-AGC CCT TGC ACC CCT CAC AG-39), mBATF (59-GTT CTG TTT CTC CAG
GTC C-39, 59-GAA GAA TCG CAT CGC TGC-39), mIRF4 (59-ACGCTGCCC
TCTTCAAGGCTT-39, 59-TGGCTCCTCTCGACCAATTCC-39), mc-maf (59-AGC
AGT TGG TGA CCA TGT CG-39, 59-TGG AGA TCT CCT GCT TGA GG-39),
mIL21 (59-CAG GAG GGG AGG AAA GAA AC-39, 59-GGG AAT CTT CTC GGA
TCC TC-39), mIL-21R (59-CTC CCC CCT TGA ACG TGA CT-39, 59-TTG CCC
CTC AGC ACG TAG TT-39). The mRNA of the genes of interest was normalized
using the mRNA levels of the housekeeping gene HPRT (59-GCC CCA AAA TGG
TTA AGG TT-39, 59-TTG CGC TCA TCT TAG GCT TT-39). For human analyses
the following primers and sequences were used: hHPRT (59- TGA CAC TGG CAA
AAC AAT GCA-39, 59- GGT CCT TTT CAC CAG CAA GCT-39), hIL-6 (59-CAA
GAC TGA ACA CCG ACT AAG-39, 59- CTG GCT CTG AAA CAA AGG AT-39)
and hT-bet (59-CAG AAT GCC GAG ATT ACT CAG-39, 59- GGT TGGGTA GGA
GAG GAG AG-39).
Statistical analysis. Differences were evaluated for significance by the Student’s two-
tailed t test for parametric data. * p# 0,05, ** p# 0,01, *** p# 0,001. Data are given
as mean values 6 s.e.m.
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